BR9910071A - Pharmaceutical composition, processes for increasing and maintaining the homogeneity of a pharmaceutical composition and for treating, reversing, reducing or inhibiting retroviral infections, use of abacavir, lamivudine, zidovudine or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable gliding agent , article of manufacture, and, process for the preparation of a pharmaceutical composition - Google Patents
Pharmaceutical composition, processes for increasing and maintaining the homogeneity of a pharmaceutical composition and for treating, reversing, reducing or inhibiting retroviral infections, use of abacavir, lamivudine, zidovudine or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable gliding agent , article of manufacture, and, process for the preparation of a pharmaceutical compositionInfo
- Publication number
- BR9910071A BR9910071A BR9910071-1A BR9910071A BR9910071A BR 9910071 A BR9910071 A BR 9910071A BR 9910071 A BR9910071 A BR 9910071A BR 9910071 A BR9910071 A BR 9910071A
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- abacavir
- lamivudine
- zidovudine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSIçãO FARMACêUTICA, PROCESSOS PARA AUMENTAR E MANTER A HOMOGENEIDADE DE UMA COMPOSIçãO FARMACêUTICA E PARA, TRATAR, REVERTER, REDUZIR OU INIBIR INFECçõES RETROVIRAIS, USO DE ABACAVIR, LAMIVUDINA, ZIDOVUDINA OU DE UM DERIVADO FARMACEUTICAMENTE ACEITáVEL DOS MESMOS, E DE UM AGENTE DE DESLIZAMENTO FARMACEUTICAMENTE ACEITáVEL, ARTIGO DE MANUFATURA, E, PROCESSO PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA" é exposta uma composição farmacêutica, que compreende uma combinação homogênea de abacavir, lamivudina, e zidovudina, em uma quantidade que alcança eficácia antiviral, um processo para a preparação de uma tal composição, e um processo para inibir o vírus de imunodeficiência humana (HIV), que compreende administrar uma tal composição a um paciente infectado com HIV."PHARMACEUTICAL COMPOSITION, PROCESSES TO INCREASE AND MAINTAIN THE HOMOGENEITY OF A PHARMACEUTICAL COMPOSITION AND TO, TREAT, REVERSE, REDUCE OR INHIBIT RETROVIRAL INFECTIONS, USE OF ABACAVIR, LAMIVUDINE, ZIDOVUDINE OR DEALING WITH A DERIVATION OF A DERIVATION PHARMACEUTICALLY ACCEPTABLE, MANUFACTURING ARTICLE, AND PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION "a pharmaceutical composition is exposed, which comprises a homogeneous combination of abacavir, lamivudine, and zidovudine, in an amount that achieves antiviral efficacy, a process for preparation for antiviral of such a composition, and a process for inhibiting the human immunodeficiency virus (HIV), which comprises administering such a composition to an HIV-infected patient.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9809213.3A GB9809213D0 (en) | 1998-04-29 | 1998-04-29 | Pharmaceutical compositions |
| PCT/EP1999/002794 WO1999055372A1 (en) | 1998-04-29 | 1999-04-26 | Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9910071A true BR9910071A (en) | 2000-12-26 |
Family
ID=10831228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9910071-1A BR9910071A (en) | 1998-04-29 | 1999-04-26 | Pharmaceutical composition, processes for increasing and maintaining the homogeneity of a pharmaceutical composition and for treating, reversing, reducing or inhibiting retroviral infections, use of abacavir, lamivudine, zidovudine or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable gliding agent , article of manufacture, and, process for the preparation of a pharmaceutical composition |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1083932A1 (en) |
| JP (1) | JP2002512979A (en) |
| KR (1) | KR20010043128A (en) |
| CN (1) | CN1411380A (en) |
| AP (1) | AP2000001971A0 (en) |
| AU (1) | AU4135599A (en) |
| BR (1) | BR9910071A (en) |
| CA (1) | CA2330391A1 (en) |
| EA (1) | EA200000997A1 (en) |
| EE (1) | EE200000646A (en) |
| GB (1) | GB9809213D0 (en) |
| HR (1) | HRP20000732A2 (en) |
| HU (1) | HUP0101622A3 (en) |
| ID (1) | ID26955A (en) |
| IL (1) | IL139181A0 (en) |
| IS (1) | IS5675A (en) |
| NO (1) | NO20005418L (en) |
| NZ (1) | NZ507745A (en) |
| PL (1) | PL343710A1 (en) |
| SK (1) | SK16212000A3 (en) |
| TR (1) | TR200003157T2 (en) |
| WO (1) | WO1999055372A1 (en) |
| ZA (1) | ZA200005922B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875773B1 (en) | 1998-05-29 | 2005-04-05 | Ben M. Dunn | Combination therapy for treatment of FIV infection |
| WO1999060988A2 (en) * | 1998-05-29 | 1999-12-02 | University Of Florida | Combination therapy for treatment of fiv infection |
| GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
| CZ20041117A3 (en) * | 2002-04-23 | 2005-04-13 | Lupin Limited | Long acting compositions comprising zidovudine and lamivudine |
| TW200403061A (en) * | 2002-06-04 | 2004-03-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| CN100335125C (en) * | 2003-06-03 | 2007-09-05 | 上海现代药物制剂工程研究中心 | Interferon nasal spray powder with long service for detoxication and anti-bacteria |
| WO2006114709A1 (en) * | 2005-04-25 | 2006-11-02 | Aurobindo Pharma Limited | Pharmaceutical compositions of antiretrovirals |
| WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
| ES2279707B1 (en) * | 2005-11-10 | 2008-06-01 | Combino Pharm, S.L. | ORAL FORMULATIONS THAT INCLUDE 3'-AZIDONUCLEOSIDS. |
| CN101878032A (en) * | 2007-10-02 | 2010-11-03 | 埃默里大学 | Potent combinations of zidovudine and drugs that select for the K65R mutation in the HIV polymerase |
| GB2470494B (en) * | 2008-01-17 | 2012-08-08 | Univ Holy Ghost Duquesne | Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS |
| ES2969969T3 (en) * | 2010-01-27 | 2024-05-23 | Viiv Healthcare Co | Combinations of dolutegravir and lamivudine for the treatment of HIV infection |
| EP2579892A2 (en) | 2010-06-09 | 2013-04-17 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment |
| US20150104511A1 (en) | 2012-03-05 | 2015-04-16 | Cipla Limited | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine |
| KR20150084772A (en) | 2012-10-23 | 2015-07-22 | 시플라 리미티드 | Pharmaceutical antiretroviral composition |
| BR112015031027A2 (en) * | 2013-06-13 | 2017-08-29 | Akebia Therapeutics Inc | USE OF A COMPOUND, IN VITRO METHOD, PHARMACEUTICAL COMPOSITION AND SINGLE DOSAGE FORM |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY115461A (en) * | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| GB9622681D0 (en) * | 1996-10-31 | 1997-01-08 | Glaxo Group Ltd | Pharmaceutical compositions |
-
1998
- 1998-04-29 GB GBGB9809213.3A patent/GB9809213D0/en not_active Ceased
-
1999
- 1999-04-26 NZ NZ507745A patent/NZ507745A/en unknown
- 1999-04-26 HU HU0101622A patent/HUP0101622A3/en unknown
- 1999-04-26 TR TR2000/03157T patent/TR200003157T2/en unknown
- 1999-04-26 IL IL13918199A patent/IL139181A0/en unknown
- 1999-04-26 BR BR9910071-1A patent/BR9910071A/en not_active IP Right Cessation
- 1999-04-26 CN CN99807983A patent/CN1411380A/en active Pending
- 1999-04-26 AP APAP/P/2000/001971A patent/AP2000001971A0/en unknown
- 1999-04-26 JP JP2000545569A patent/JP2002512979A/en active Pending
- 1999-04-26 EA EA200000997A patent/EA200000997A1/en unknown
- 1999-04-26 ID IDW20002479A patent/ID26955A/en unknown
- 1999-04-26 CA CA002330391A patent/CA2330391A1/en not_active Abandoned
- 1999-04-26 SK SK1621-2000A patent/SK16212000A3/en unknown
- 1999-04-26 PL PL99343710A patent/PL343710A1/en unknown
- 1999-04-26 EP EP99924822A patent/EP1083932A1/en not_active Withdrawn
- 1999-04-26 KR KR1020007012021A patent/KR20010043128A/en not_active Application Discontinuation
- 1999-04-26 WO PCT/EP1999/002794 patent/WO1999055372A1/en not_active Application Discontinuation
- 1999-04-26 EE EEP200000646A patent/EE200000646A/en unknown
- 1999-04-26 AU AU41355/99A patent/AU4135599A/en not_active Abandoned
-
2000
- 2000-10-20 IS IS5675A patent/IS5675A/en unknown
- 2000-10-23 ZA ZA200005922A patent/ZA200005922B/en unknown
- 2000-10-27 HR HR20000732A patent/HRP20000732A2/en not_active Application Discontinuation
- 2000-10-27 NO NO20005418A patent/NO20005418L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20000732A2 (en) | 2001-02-28 |
| PL343710A1 (en) | 2001-08-27 |
| CN1411380A (en) | 2003-04-16 |
| SK16212000A3 (en) | 2001-07-10 |
| NO20005418L (en) | 2000-11-29 |
| WO1999055372A1 (en) | 1999-11-04 |
| CA2330391A1 (en) | 1999-11-04 |
| ID26955A (en) | 2001-02-22 |
| EE200000646A (en) | 2002-04-15 |
| HUP0101622A2 (en) | 2002-03-28 |
| JP2002512979A (en) | 2002-05-08 |
| IS5675A (en) | 2000-10-20 |
| ZA200005922B (en) | 2001-10-23 |
| HUP0101622A3 (en) | 2003-09-29 |
| EP1083932A1 (en) | 2001-03-21 |
| AU4135599A (en) | 1999-11-16 |
| AP2000001971A0 (en) | 2000-12-31 |
| GB9809213D0 (en) | 1998-07-01 |
| KR20010043128A (en) | 2001-05-25 |
| EA200000997A1 (en) | 2001-06-25 |
| NO20005418D0 (en) | 2000-10-27 |
| NZ507745A (en) | 2004-07-30 |
| IL139181A0 (en) | 2001-11-25 |
| TR200003157T2 (en) | 2001-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9910071A (en) | Pharmaceutical composition, processes for increasing and maintaining the homogeneity of a pharmaceutical composition and for treating, reversing, reducing or inhibiting retroviral infections, use of abacavir, lamivudine, zidovudine or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable gliding agent , article of manufacture, and, process for the preparation of a pharmaceutical composition | |
| BR9813373A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient | |
| EP0349242A3 (en) | Therapeutic nucleosides | |
| PT100199A (en) | Antiviral Combination of Nucleosides and Process for Preparation | |
| CA2293470A1 (en) | Benzimidazole derivatives | |
| YU7296A (en) | Novel pharmaceutical combination containing antivirus substance and one anti-inflamatory glucocorticoid | |
| BR0008840A (en) | Camptothecin derivatives having antitumor activity | |
| BR9811121A (en) | Product, pharmaceutical composition, and use of a product | |
| ES2186714T3 (en) | USE OF ALPHA 8 SIMPLE SUBSTITUTE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF VIRAL INFECTIONS OF THE LIVER. | |
| HUP0302334A2 (en) | Antiviral prodrugs | |
| MY104575A (en) | Therapeutic nucleosides. | |
| BR0012488A (en) | Pharmaceutical composition, methods for improving the absorption rate of one or more than one pharmaceutically active agent in mammals, for improving the onset of the therapeutic benefit of one or more than one pharmaceutically active agent in mammals, for inhibiting gastroirritation in a mammal. , and for treating mammals requiring treatment provided by one or more than one pharmaceutically active agent, and, process for preparing a pharmaceutical composition. | |
| BRPI0112962B8 (en) | pharmaceutical compositions comprising hyaluronic acid, glycyrrhetinic acid and polyvinylpyrrolidone, and use of these compounds in the preparation of medicines | |
| EP0293826A3 (en) | Therapeutic and prophylactic application of sulfated polysaccharides against aids | |
| KR890003387A (en) | Double-stranded RMAs Composition with Local Activity | |
| BR9712614A (en) | Pharmaceutical composition, processes for increasing and maintaining the homogeneity of a pharmaceutical & eutectic composition, for treating, reversing, reducing or inhibiting retroviral infections and for preparing a pharmaceutical composition, use of lamivudine or a pharmaceutically acceptable derivative thereof, of zidovudine, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable glidant; and, an article of manufacture. | |
| DK0484112T3 (en) | Use of lithium in the treatment or prophylaxis of Molluscum contagiosum | |
| BR0206775A (en) | Use of a drug to treat an HIV-infected individual by combining immunization with structured interruption of antiretroviral treatment | |
| BR9916043A (en) | Compound, use of the same and its pharmaceutically acceptable salts, and pharmaceutical composition for the treatment of viral herpes infections in patients | |
| BR9808060A (en) | Pharmaceutical composition, processes for treating viral infections by administering a pharmaceutically safe and effective amount of a pharmaceutical composition, use of lamivudine or a pharmaceutically acceptable derivative thereof, and process for the preparation of a pharmaceutical composition. | |
| MY105855A (en) | Therapeutic nucleotides. | |
| PT99057A (en) | A PROCESS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS CONTAINING A SYNERGIC MIXTURE OF GLYCOPROTEIN CD4 FROM THE SURFACE OF THE ECELULAS OR AN ANALYTICAL COMPONENT WITH AN ANTI-HIV POLYURIC AGENT, PARTICULARLY A SULFATED POLYNOSTAIN | |
| ES2101850T3 (en) | TOPICAL COMPOSITION THAT ENHANCES THE HEALING OF HERPES INJURIES. | |
| DE68900760D1 (en) | VIRUS INHIBITING NUCLEOSIDE MIXTURE. | |
| ES2130246T3 (en) | THERAPEUTIC NUCLEOSIDES SERIES 2 ', 3'-DIDESOXI-3'-FLUORO-PURINA. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |